Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
2007-08-28
2007-08-28
Nickol, Gary B. (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
C530S402000, C530S387300, C424S185100, C424S192100, C435S069100, C435S252300, C435S430100, C435S320100, C435S235100, C435S325000, C536S023100, C536S024310
Reexamination Certificate
active
10405878
ABSTRACT:
Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
REFERENCES:
patent: 5670319 (1997-09-01), Goeddel et al.
patent: 5710013 (1998-01-01), Goeddel et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5767244 (1998-06-01), Goeddel et al.
patent: 5789550 (1998-08-01), Goeddel et al.
patent: 5843678 (1998-12-01), Boyle
patent: 5961974 (1999-10-01), Armitage et al.
patent: 6015938 (2000-01-01), Boyle et al.
patent: 6017729 (2000-01-01), Anderson et al.
patent: 6150090 (2000-11-01), Baltimore et al.
patent: 6242213 (2001-06-01), Anderson
patent: 6242586 (2001-06-01), Gorman et al.
patent: 6271349 (2001-08-01), Dougall et al.
patent: 6316408 (2001-11-01), Boyle
patent: 6410516 (2002-06-01), Baltimore et al.
patent: 6419929 (2002-07-01), Anderson
patent: 6525180 (2003-02-01), Gorman et al.
patent: 6528482 (2003-03-01), Anderson et al.
patent: 6537763 (2003-03-01), Dougall et al.
patent: 6740522 (2004-05-01), Anderson
patent: 0816380 (1998-01-01), None
patent: 0873998 (1998-10-01), None
patent: 0911342 (1999-04-01), None
patent: 0955372 (1999-11-01), None
patent: WO93/08207 (1993-04-01), None
patent: WO95/33051 (1995-12-01), None
patent: WO96/34095 (1996-10-01), None
patent: WO97/23614 (1997-07-01), None
patent: WO98/25958 (1998-06-01), None
patent: WO98/28423 (1998-07-01), None
patent: WO98/46751 (1998-10-01), None
patent: WO98/54201 (1998-12-01), None
patent: WO99/29865 (1999-06-01), None
patent: WO99/65449 (1999-12-01), None
patent: WO99/65495 (1999-12-01), None
patent: WO 01/23549 (2001-04-01), None
patent: WO 02/15846 (2002-02-01), None
Anderson et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function,”Nature390:175-179, 1997.
Baker, Stacey J. and Reddy, E. Premkumar, “Transducers of life and death: TNF receptor superfamily and associated proteins,”Oncogene, 12(1):1-9, 1996.
Boylev.Gorman and Mattson, Board of Patent Appeals and Interferences, Interference No. 104,336, Paper No. 39.
Camerini et al., “The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family,”J. Immunol.147:3165, 1991.
Durkop et al., “Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's Disease,”Cell68:421, 1992.
Embl database entry HS421358; accession No. W74421,Homo sapienscDNA clone 346544 containing alu repetitive element, Hillier et al., Jun. 1996.
Embl-est database accession No. R93478, yq16f06.rlHomo sapiancDNA clone 197123 5' sequence, Hillier et al., Aug. 1995.
Galibert et al., “The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-?B, a member of the TNFR superfamily,”J. Biol. Chem.273(51):34120-34127, 1998.
GenEmbl database accession No. X15271, locus.HSTRGV3F, human T-cell receptor gammaV3F, Lefranc, M. P., Mar. 1991.
George et al., Current methods in sequence comparison and analysis, selected methods and applications, eds. David H. Schlesinger, Alan R. Liss, Inc., New York, pp. 124-129, 1988.
Gibbs, Jackson B. and Oliff, Allen, “Pharmaceutical research in molecular oncology,”Cell, 79:193-198, 1994.
Gray et al., “P-element-induced recombination in drosophila melanogaster: hybrid element insertion,”Genetics144(4):1601-1610, 1996.
Guise, Theresa A. and Mundy, Gregory R., “Cancer and bone,”Endocrine Reviews 19(1):18-54,1998.
Huang, Jing and Schreiber, Stuart L., “A yeast genetic system for selecting small molecule inhibitors of protein-protein interaction in nanodroplets,”Proc. Natl. Acad. Sci. USA, 94:13396-13401, 1997.
Itoh et al., “The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis,”Cell66:233, 1991.
Johnson et al., “Expression and structure of the human NGF receptor,”Cell47:545, 1986.
Kodaira et al., “Cloning and characterization of the gene encoding mouse osteoclast differentiation factor,”Gene230:121-127, 1999.
Kwon et al., “cDNA sequences of two inducible T-cell genes,”Proc. Natl. Acad. Sci. USA86:1963, 1989.
Lacey et al., “Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation,”Cell, 93:165-175, 1998.
Lynch et al, “A fluorescence polarization based Src-SH2 binding assay,”Analytical Biochemistry, 247:77-82, 1997.
Mallet et al., “Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes—a molecule related to nerve growth factor receptor,”EMBO J.9:1063, 1990.
Nakagawa et al., “RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis,”Biochem. and Biophys. Res. Comm.253:395-400, 1998.
Pullen et al., “CD40—tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization,”Biochemistry37(34):11836-11845, 1998.
Roodman, G. David, “Advances in bone biology: the osteoclast,”Endocr Rev.17(4):308-332, 1996.
Rossi et al., “Monitoring protein-protein interactions in intact eukaryotic cells by β-galactosidase complementation,”Proc. Natl. Acad. Sci. USA91:8405-8410, 1997.
Rothe, M. et al., “The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins,”Cell83:1243-1252, 1995.
Schall et al., “Molecular cloning and expression of a receptor for human tumor necrosis factor,”Cell61:361, 1990.
Simonet et al., “Osteoprotegerin: A novel secreted protein involved in the regulation of bone density,”Cell89:309-319, 1997.
Smith, C. et al., “A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins,”Sci.248:1019-1022, 1990.
Stamenkovic et al., “A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas,”EMBO J.8:1403, 1989.
Suda et al., “Modulation of osteoclast differentiation by local factors,”Bone 17(2):87S-91S; 1995.
Suda et al., “Modulation of osteoclast differentiation,”Endocr Rev. 13: 66-80, 1992.
Suda et al., “Modulation of osteoclast differentiation: update 1995,” inEndocr Rev. Monographs,4(1):266-270; 1995.
Takahashi N et al., “A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function,”Biochem Biophys Res Commun1999; 256:449-455.
Tsukii K et al., “Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1α,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone,”Biochem Biophys Res Commun1998; 246:337-341.
White, Michael A., “The yeast two-hybrid system: forward and reverse,”Proc. Natl. Acad. Sci. USA, 93:10001-10003, 1996.
Wiley, SR et al., “Identification and characterization of a new member of the TNF family that induces apoptosis,”Immunity1995; 3(6):673-682.
Wong et al., “TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells,”J. of Biological Chemistry272(40):25190-25194, 1997.
Wong et al., “TRANCE (Tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor,”J. Exp. Med.186(12):2075-2080, 1997.
Wong et al., “The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor,”J. Biol. Chem.273(43):28355-28359,
Ausenhus Scott L.
Basi Nirmal S.
Immunex Corporation
Nickol Gary B.
LandOfFree
Kits containing rank polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kits containing rank polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kits containing rank polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3839667